ADVANCES IN ANTIFUNGAL THERAPY FOR ONCHOMYCOSIS: A FOCUS ON EMERGING AGENTS AND TECHNOLOGIES
DOI:
https://doi.org/10.22159/ajpcr.2025v18i10.55391Keywords:
Antifungal therapy, onychomycosis, next-generation antifungals, fungal biofilms, drug resistance, photodynamic therapy, nanotechnologyAbstract
Onychomycosis, a persistent fungal infection of the nails, is a therapeutic challenge because of its high recurrence, poor drug penetration, and resistance developed by the fungus to common antifungals (AFs). “The available therapies, such as oral azoles and topicals, can have limited efficacy, lengthy duration of treatment, or potential side effects,” they added. This has created a demand for new and better AF tactics. Novel AFs whose development has been fueled by recent advances in our understanding about fungal biology are the newer (most are second-line for invasive mycoses) broad-spectrum systemic agents with superior pharmacokinetic profiles and lower toxicities, as seen with improved azole derivatives and allylamines. Systemic AF therapy nanotechnology-mediated drug delivery systems, such as nanoparticle encapsulated AFs and liposomal formulations, have promising potential for increased drug penetration and therapeutic efficacy. In resistant cases, non-pharmacological measures such as photodynamic therapy and lasers are increasingly being considered. In addition, emerging approaches, such as microbiome-targeted interventions and RNA-based treatments, provide new methods for addressing fungal biofilms and recalcitrant infections. However, significant challenges exist in the translation of these novel therapies into clinical practice, and research efforts continue to be made toward refining modifications of treatment algorithms and enhancing patient efficacy. The present review summarizes the new therapeutic approaches to onychomycosis with a special emphasis on the mechanism, clinical efficacy, and future development. The convergence of innovative anti-fibrotic agents (AFs), nanotechnology, and novel therapeutic approaches holds promise for the development of more efficacious and tolerable treatments in the near future.
Downloads
References
1. Gupta AK, Versteeg SG, Shear NH. Onychomycosis in the 21st century: An update on diagnosis, epidemiology, and treatment. J Cutan Med Surg. 2017 Nov;21(6):525-39. doi: 10.1177/1203475417716362, PMID 28639462
2. Jan S, Bora D, Bhise K. Preungual drug delivery systems of terbinafine hydrochloride nail lacquer. Asian J Pharm. 2014;2(1):1-7.
3. Hamm H, Stolze I. Diseases of nails. In: Plewig G, French L, Ruzicka T, Kaufmann R, Hertl M, editors. Braun-Falco’s Dermatology. Berlin, Heidelberg: Springer; 2022 Apr 28. p. 1373-98. doi: 10.1007/978-3- 662-63709-8_74
4. Desai D, Patel P. Terbinafine microparticle nail lacquer: Optimization using factorial design. Int J Curr Res. 2016;8(12):450-7.
5. Gupta AK, Albreski D, Del Rosso JQ, Konnikov N. The use of the new oral antifungal agents, itraconazole, terbinafine, and fluconazole to treat onychomycosis and other dermatomycoses. Curr Probl Dermatol. 2001 Aug 1;13(4):213-46. doi: 10.1067/mdm.2001.108128
6. Kaur S, Singh D. Clinical evaluation of terbinafine lacquer in mild onychomycosis. Int J Pharm Phytopharmacol Res. 2017;9(2):141-8.
7. Baswan S, Kasting GB, Li SK, Wickett R, Adams B, Eurich S, et al. Understanding the formidable nail barrier: A review of the nail microstructure, composition and diseases. Mycoses. 2017 May;60(5):284-95. doi: 10.1111/myc.12592, PMID 28098391
8. Sekyere JO, Asante J. Emerging mechanisms of antimicrobial resistance in bacteria and fungi: Advances in the era of genomics. Future Microbiol. 2018 Feb 1;13(2):241-62. doi: 10.2217/fmb-2017- 0172, PMID 29319341
9. Sharma P, Verma P. Formulation and evaluation of terbinafine nail lacquer: An ex vivo study. Int J Pharm Phytopharmacol Res. 2015;5(1):30-7.
10. Zobi C, Algul O. The significance of mono- and dual-effective agents in the development of new antifungal strategies. Chem Biol Drug Des. 2025 Jan;105(1):e70045. doi: 10.1111/cbdd.70045, PMID 39841631
11. Rao S, Mehta G. Terbinafine niosomal gel: Formulation and antifungal activity against Trichophyton rubrum. Int J Pharm Phytopharmacol Res. 2017;7(4):215-22.
12. Srivastava R, Rawat AK, Mishra MK, Patel AK. Advancements in nanotechnology for enhanced antifungal drug delivery: A comprehensive review. Infect Disord Drug Targets. 2024 Mar 1;24(2):e021123223053. doi: 10.2174/0118715265266257231022134933, PMID 38291868
13. Ailioaie LM, Litscher G. Probiotics, photobiomodulation, and disease management: Controversies and challenges. Int J Mol Sci. 2021 May 6;22(9):4942. doi: 10.3390/ijms22094942, PMID 34066560
14. Priya N, Reddy B. Comparative permeation study of terbinafine-loaded ethosomes and niosomes. Int J Curr Pharm Res. 2018;10(2):45-51.
15. Kumar A, Dash S. Quality by design-driven nanosphere gel of terbinafine for topical onychomycosis treatment. Int J Curr Pharm Res. 2019;11(3):120-9.
16. Tosti A, Hay RJ, Arenas R, Torchia D, Garcia-Romero MT, Londono JC, et al. Global consensus for the definition of onychomycosis. Skin Appendage Disord. 2017;3(3):167-71.
17. Westerberg DP, Voyack MJ. Onychomycosis: Current trends in diagnosis and treatment. Am Fam Physician. 2013;88(11):762-70. PMID 24364524
18. Gupta AK, Simpson FC. Diagnosing onychomycosis. Clin Dermatol. 2013;31(5):540-3. doi: 10.1016/j.clindermatol.2013.06.009, PMID 24079582
19. Elewski BE. Onychomycosis: Pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998;11(3):415-29. doi: 10.1128/ CMR.11.3.415, PMID 9665975
20. Hay RJ. Onychomycosis. Curr Fungal Infect Rep. 2009;3(3):123-7.
21. Scher RK, Baran R. Onychomycosis in clinical practice: Factors contributing to recurrence. Br J Dermatol. 2003;149(Suppl 65):5-9. doi: 10.1046/j.1365-2133.149.s65.5.x, PMID 14510969
22. Gupta AK, Paquet M. Systematic review of the epidemiology of onychomycosis in children. Br J Dermatol. 2013;168(3):455-66.
23. Piraccini BM, Alessandrini A. Onychomycosis: A review. J Fungi (Basel). 2015;1(1):30-43. doi: 10.3390/jof1010030, PMID 29376897
24. Thomas J, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, Sharpe C. Toenail onychomycosis: An important global disease burden. J Clin Pharm Ther. 2010;35(5):497-519. doi: 10.1111/j.1365- 2710.2009.01107.x, PMID 20831675
25. Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population: A literature study. J Eur Acad Dermatol Venereol. 2014;28(11):1480-91. doi: 10.1111/jdv.12323, PMID 24283696
26. Patel H, Shah N. In-vitro evaluation of polymeric nail lacquer containing terbinafine HCl. Int J Curr Res. 2020;12(5):256-63.
27. Singh R, Jain A. Green synthesis of niosomal terbinafine: Characterization and antimicrobial efficacy. Int J Pharm Phytopharmacol Res. 2021;11(1):78-86.
28. Verma R, Gupta AK. Transungual delivery of terbinafine via nanoemulgel: Formulation and hoof membrane permeation. Int J Curr Pharm Res. 2021;13(4):98-105.
29. Foley K, Gupta AK, Versteeg S, Mays R, Villanueva E, John D. Topical and device-based treatments for fungal infections of the toenails. Cochrane Database Syst Rev. 2020;1(1):CD012093. doi: 10.1002/14651858.cd012093.pub2, PMID 31978269
30. Michel MC, Gubler CJ. Onychomycosis: Rapid evidence review. Am Fam Physician. 2021 Oct 1;104(7):359-64.
31. Oliveira M, Pereira MM, Costa JG. Network meta-analysis of onychomycosis treatments. J Eur Acad Dermatol Venereol. 2016;30(9):144-52.
32. Chanyachailert P, Leeyaphan C, Bunyaratavej S. Cutaneous fungal infections caused by dermatophytes and non-dermatophytes: An updated comprehensive review of epidemiology, clinical presentations, and diagnostic testing. J Fungi (Basel). 2023 Jun 14;9(6):669. doi: 10.3390/jof9060669, PMID 37367605
33. Megson ML, Smith WP, Clark DC, Martin MV. Safety and pharmacokinetics of 10% terbinafine hydrochloride nail lacquer in patients with onychomycosis: A phase I, double-blind, randomized, placebo-controlled study. Bethesda: Clin Trials Registry; 2008 Jun 3. 34. Roilides E, Simitsopoulou M, Katragkou A, Walsh TJ. How biofilms evade host defenses. Microbiol Spectr. 2015 Oct 7;3(3):287-300. doi: 10.1128/microbiolspec.MB-0012-2014, PMID 26185085.
35. Garcia ÍR, De Oliveira Garcia FA, Pereira PS, Coutinho HD, Siyadatpanah A, Norouzi R, et al. Microbial resistance: The role of efflux pump superfamilies and their respective substrates. Life Sci. 2022 Apr 15;295:120391. doi: 10.1016/j.lfs.2022.120391, PMID 35149116
36. Salve PS. Development and evaluation of topical drug delivery system for terbinafine hydrochloride using niosomes. Res J Top Cosmet Sci. 2011;2(2):52-63.
37. Gil MF. Onychomycosis: A Review of Current Pharmacological and Non-Pharmacological Treatment Options [Dissertation]. PQDT-Global; 2022.
38. Blutfield MS, Lohre JM, Pawich DA, Vlahovic TC. The immunologic response to Trichophyton rubrum in lower extremity fungal infections. J Fungi (Basel). 2015 Jul 17;1(2):130-7. doi: 10.3390/jof1020130, PMID 29376904
39. Hameed S, editor. Human Fungal Diseases: Diagnostics, Pathogenesis, Drug Resistance and Therapeutics. Boca Raton: CRC Press; 2024 Sep 17. doi: 10.1201/9781032642864
40. Murdan S. Nail disorders in older people, and aspects of their pharmaceutical treatment. Int J Pharm. 2016 Oct 30;512(2):405-11. doi: 10.1016/j.ijpharm.2016.05.022, PMID 27180233
41. Javanmard Z, Pourhajibagher M, Bahador A. Advancing anti-biofilm strategies: Innovations to combat biofilm-related challenges and enhance efficacy. J Basic Microbiol. 2024 Dec;64(12):e2400271. doi: 10.1002/jobm.202400271, PMID 39392011
42. K.M. Semnani et.al, Green formulation, characterization, antifungal and biological safety evaluation of terbinafine HCl niosomes and niosomal gels manufactured by eco-friendly green method. J Biomater Sci Polym Ed 2022;33:2325-2352. doi: 10.1080/09205063.2022.2103626.
43. Hoenigl M, Arastehfar A, Arendrup MC, Brüggemann R, Carvalho A, Chiller T, et al. Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease. Clin Microbiol Rev. 2024 Jun 13;37(2):e0007423. doi: 10.1128/cmr.00074- 23, PMID 38602408
44. Pathak MK, Srivastava S, Singh RP. Bilayered nail lacquer of terbinafine hydrochloride for onychomycosis: In vitro and clinical evaluation. J Pharm Sci. 2010;99(10):4452-61.
45. Roy M, Karhana S, Shamsuzzaman M, Khan MA. Recent drug development and treatments for fungal infections. Braz J Microbiol. 2023 Sep;54(3):1695- 716. doi: 10.1007/s42770-023-00999-z, PMID 37219748
46. Sharma A, Kaur J, Vyas SP. Terbinafine hydrochloride nail lacquer: Formulation, characterization and in vitro evaluation. J Drug Deliv Sci Technol. 2018;44:34-42.
47. Shah VH, Jobanputra A. Enhanced ungual permeation of terbinafine HCl delivered through liposome-loaded nail lacquer optimized by QbD approach. AAPS PharmSciTech. 2018;19(1):213-24. doi: 10.1208/ s12249-017-0831-0, PMID 28681334
48. Lewis JS, Wiederhold NP, Hakki M, Thompson GR 3rd. New perspectives on antimicrobial agents: Isavuconazole. Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0017722. doi: 10.1128/ aac.00177-22, PMID 35969068
49. Hammoudi Halat D, Younes S, Mourad N, Rahal M. Allylamines, benzylamines, and fungal cell permeability: A review of mechanistic effects and usefulness against fungal pathogens. Membranes (Basel). 2022 Nov 22;12(12):1171. doi: 10.3390/membranes12121171, PMID 36557078
50. Gupta AK, Venkataraman M, Quinlan EM. New antifungal agents and new formulations against dermatophytes. In: Dermatophytes and Dermatophytoses. Cham: Springer International Publishing; 2021 Jun 9. p. 433-71.
51. Gupta AK, Versteeg SG. Tavaborole-a treatment for onychomycosis of the toenails. Expert Rev Clin Pharmacol. 2016 Sep 1;9(9):1145-52. doi: 10.1080/17512433.2016.1206467, PMID 27347905
52. Nagasa GD, Belete A. Review on nanomaterials and nano-scaled systems for topical and systemic delivery of antifungal drugs. J Multidiscip Healthc. 2022 Jan 1;15:1819-40. doi: 10.2147/jmdh. s359282, PMID 36060421
53. Gupta AK, Surprenant MS, Kempers SE, Pariser DM, Rensfeldt K, Tavakkol A. Efficacy and safety of topical terbinafine 10% solution (MOB-015) in mild-moderate DLSO: Phase 3 RCT. J Am Acad Dermatol. 2021;85(1):95-104. doi: 10.1016/j.jaad.2020.06.055, PMID 32585278
54. Jensen-Pergakes KL, Kennedy MA, Lees ND, Barbuch R, Koegel C, Bard M. Sequencing, disruption, and characterization of the Candida albicans sterol methyltransferase (ERG6) gene: Drug susceptibility studies in erg6 mutants. Antimicrob Agents Chemother. 1998 May 1;42(5):1160- 7. doi: 10.1128/AAC.42.5.1160, PMID 9593144
55. Konisky H, Klinger R, Coe L, Jaller JA, Cohen JL, Kobets K. A focused review on laser- and energy-assisted drug delivery for nail disorders. Lasers Med Sci. 2024 Jan 19;39(1):39. doi: 10.1007/s10103-024- 03992-6, PMID 38240827
56. Baran R, Sigurgeirsson B, De Berker D, Kaufmann R, Lecha M, Faergemann J, et al. Multicentre RCT: Amorolfine lacquer + oral terbinafine vs oral terbinafine alone in onychomycosis. Br J Dermatol. 2007;157(1):149-57. doi: 10.1111/j.1365-2133.2007.07974.x, PMID 17553051
57. Oliveira M, Pereira MM, Costa JG. Network meta-analysis of onychomycosis treatments. J Eur Acad Dermatol Venereol. 2016;30(9):144-52.
58. Ahmad F, Salem-Bekhit MM, Khan F, Alshehri S, Khan A, Ghoneim MM, et al. Unique properties of surface-functionalized nanoparticles for bio-application: Functionalization mechanisms and importance in application. Nanomaterials (Basel). 2022 Apr 13;12(8):1333. doi: 10.3390/nano12081333, PMID 35458041
59. Sousa F, Ferreira D, Reis S, Costa P. Current insights on antifungal therapy: Novel nanotechnology approaches for drug delivery systems and new drugs from natural sources. Pharmaceuticals (Basel). 2020 Sep 15;13(9):248. doi: 10.3390/ph13090248, PMID 32942693
60. Guo YX, He YX. Nanoparticle-based drug delivery systems: An updated strategy for treating fungal keratitis. Colloids Interface Sci Commun. 2024 Jul 1;61:100794. doi: 10.1016/j.colcom.2024.100794
61. Carita AC, Eloy JO, Chorilli M, Lee RJ, Leonardi GR. Recent advances and perspectives in liposomes for cutaneous drug delivery. Curr Med Chem. 2018 Feb 1;25(5):606-35. doi: 10.2174/0929867324666171009 120154, PMID 28990515
62. Maddiboyina B, Sivaraman G. Bioinspired nanomaterials for drug delivery. Mater res Found. 2021 Oct 15;111:63-95.
63. Delattin N, Cammue BP, Thevissen K. Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilms. Future Med Chem. 2014 Jan 1;6(1):77-90. doi: 10.4155/fmc.13.189, PMID 24358949
64. Wu S, Guo W, Li B, Zhou H, Meng H, Sun J, et al. Progress of polymer-based strategies in fungal disease management: Designed for different roles. Front Cell Infect Microbiol. 2023 Mar 22;13:1142029. doi: 10.3389/fcimb.2023.1142029, PMID 37033476
65. Kaur M, Shivgotra R, Bhardwaj N, Saini S, Thakur S, Jain SK. Nascent nanoformulations as an insight into the limitations of the conventional systemic antifungal therapies. Curr Drug Targets. 2023 Feb 1;24(2):171- 90. doi: 10.2174/1389450124666221128122836, PMID 36443967
66. Mosallam S, Albash R, Abdelbari MA. Advanced vesicular systems for antifungal drug delivery. AAPS PharmSciTech. 2022 Jul 28;23(6):206. doi: 10.1208/s12249-022-02357-y, PMID 35896903
67. Boateng J, Catanzano O. Silver and silver nanoparticle-based antimicrobial dressings. In: Boateng J, editor. Therapeutic Dressings and Wound HEALING APPLications. Chichester: John Wiley and Sons; 2020 Mar 2. p. 157-84. doi: 10.1002/9781119433316.ch8
68. Sun Q, Li J, Le T. Zinc oxide nanoparticle as a novel class of antifungal agents: Current advances and future perspectives. J Agric Food Chem. 2018 Oct 9;66(43):11209-20. doi: 10.1021/acs.jafc.8b03210, PMID 30299956
69. Agrawal V, Patel R, Patel M. Design, characterization, and evaluation of efinaconazole loaded poly(D,L-lactide-co-glycolide) nanocapsules for targeted treatment of onychomycosis. J Drug Deliv Sci Technol. 2023 Feb 1;80:104157. doi: 10.1016/j.jddst.2023.104157
70. Akhtar N, Verma A, Pathak K. Topical delivery of drugs for the effective treatment of fungal infections of skin. Curr Pharm Des. 2015 Jun 1;21(20):2892-913. doi: 10.2174/1381612821666150428150 456, PMID 25925110
71. Wang L, Hu C, Shao L. The antimicrobial activity of nanoparticles: Present situation and prospects for the future. Int J Nanomedicine. 2017;12:1227-49. doi: 10.2147/IJN.S121956, PMID 28243086
72. Sethi SK, Goel H, Chawla V. Nanoemulsion based supramolecular drug delivery systems for therapeutic management of fungal infections. Drug Deliv Lett. 2024;14(1):2-15. doi: 10.2174/221030311366623091 5103016
73. Dembskey N, Abrahamse H. The efficacy of phototherapy for the treatment of onychomycosis: An observational study. Photonics. 2021;8(9):350. doi: 10.3390/photonics8090350
Published
How to Cite
Issue
Section
Copyright (c) 2025 Yogita Tyagi, Arti Kori
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
